Navigation Links
Cylex Announces Brad L. Stewart as President of the Company
Date:4/8/2008

Mr. Stewart brings critical experience in strategic and operational

leadership to support expansion of the Company's current and future

opportunities

COLUMBIA, Md., April 8, 2008 /PRNewswire/ -- Cylex(TM) has announced the appointment of Brad L. Stewart as President of the Company. Cylex is a global life sciences company that develops and manufactures research and in vitro diagnostic products based on its patented technology to assay cell-mediated immunity (CMI).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080408/NETU096 )

"A major priority for Cylex has been the recruitment of an experienced leader who could bring greater focus to the company and convert our extraordinary patented technology assets into profitable product opportunities," said Seth Rudnick, MD, General Partner in Canaan VII (a Canaan Partners fund), a major investor in Cylex, in announcing Mr. Stewart's appointment. "We believe Brad is the individual who brings us that skill set."

"I am delighted to have been given this opportunity to join Cylex and to focus first and foremost on ways to expand the awareness of our first marketed product, the ImmuKnow(R) assay, within and beyond the transplant community," says Mr. Stewart. "I have already had the chance to identify means to accelerate understanding of the value of this technology in specific therapeutic areas. We are also convinced that Cylex can rapidly expand ex-US use of ImmuKnow to support patient care in many other countries. This is an exciting challenge for me personally, and I will have the backing of a talented team of professionals at Cylex who, I know, are eager to work with me in achieving very specific goals."

Mr. Stewart brings extensive leadership experience in the life sciences industry -- with biotech, pharmaceutical, orphan drug, diagnostic and related healthcare companies. Among other accomplishments, he established a new US business for a European pharmaceutical company; drove the strategic restructuring of the North American business unit of a global pharmaceutical company; created an operational improvement business within a major diagnostics company; and developed and managed joint ventures, including a multi-million dollar joint-venture with one of the world's largest pharmaceutical companies.

At Cylex, he will have full responsibility for global commercial operations, corporate strategy and business development.

About Cylex(TM) Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow(R) is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the US and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The Company is based in Columbia, MD.


'/>"/>
SOURCE Cylex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
2. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
3. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
4. Martek Announces Final Judgment and Order of Dismissal in Class Action
5. Microbia Announces Name Change to Ironwood Pharmaceuticals
6. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
7. Medicsight Announces New Marketing Partnership with INFINITT
8. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
Breaking Biology Technology:
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):